Effectiveness of climatotherapy at the Dead Sea for psoriasis vulgaris: A community-oriented study introducing the 'Beer Sheva Psoriasis Severity Score'

Journal of Dermatological Treatment

Volumn 16, Issue 5-6, 2005, Pages 308-313

  Cohen, Arnon D ^a,b,c   Van Dijk, Dina ^b   Naggan, Lechaim ^b   Vardy, Daniel A ^a,b  

^a CLALIT HEALTH SERVICES   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c NONE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLIMATOTHERAPY; COMMUNITY; CORRELATION ANALYSIS; DISEASE SEVERITY; FACE; FEMALE; FOOT SOLE; HAND PALM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NAIL; PHYSICIAN; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSYCHOLOGICAL ASPECT;

ADULT; AGED; BALNEOLOGY; FEMALE; HELIOTHERAPY; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; THALASSOTHERAPY; TREATMENT OUTCOME;

EID: 31644445003     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630500375841     Document Type: Article

References (34)

1. Abel EA, Barnes S, Le Vine MJ, Seidman DR, Wallk S. Psoriasis treatment at the Dead Sea: Second International Study Tour. J Am Acad Dermatol. 1988;19(2 Pt 1):362-4.
2. Abels DJ, Kattan-Byron J. Psoriasis treatment at the Dead Sea: a natural selective ultraviolet phototherapy. J Am Acad Dermatol. 1985;12:639-43.
3. Abels DJ, Harari M. Psoriasis remission time at the Dead Sea. J Am Acad Dermatol. 2000;43(2 Pt 1):325-6.
4. Azizi E, Kushelevsky AP, Avrach W, Schewach-Millet M. Climate therapy for psoriasis at the Dead Sea, Israel. Isr J Med Sci. 1982;18:267-70.
5. David M, Efron D, Hodak E, Even-Paz Z. Treatment of psoriasis at the Dead Sea: why, how and when? Isr Med Assoc J. 2000;2:232-4.
6. Duvic M, Goldberg G, Prawer SE, Brenn P, Hefter HS. Climatotherapy of psoriasis at the Dead Sea. J Am Acad Dermatol. 1986;15:1298-301.
7. Duvic M. Possible mechanisms of effectiveness of Dead Sea balneotherapy. J Am Acad Dermatol. 1986;15(5 Pt 1):1061.
8. Even-Paz Z. Dermatology at the Dead Sea spas. Isr J Med Sci. 1996;32(Suppl):S11-S15.
9. Even-Paz Z, Efron D. Determination of solar ultraviolet dose in the Dead Sea treatment of psoriasis. Isr Med Assoc J. 2003;5:87-8.
10. Gambichler T, Altmeyer P, Hoffmann K. Cost-effectiveness of Dead-Sea climatotherapy and balneophototherapy of psoriasis. Int J Dermatol. 2001;40:158-9.
11. Halevy S, Sukenik S. Different modalities of spa therapy for skin diseases at the Dead Sea area. Arch Dermatol. 1998;134:1416-20.
12. Halevy S, Giryes H, Friger M, Grossman N, Karpas Z, Sarov B, et al. The role of trace elements in psoriatic patients undergoing balneotherapy with Dead Sea bath salt. Isr Med Assoc J. 2001;3:828-32.
13. Harari M, Shani J. Demographic evaluation of successful antipsoriatic climatotherapy at the Dead Sea (Israel) DMZ Clinic. Int J Dermatol. 1997;36:304-8.
14. Harari M, Shani J, Hristakieva E, Stanimirovic A, Seidl W, Burdo A. Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea. Int J Dermatol. 2000;39:913-18.
15. Hodak E, Gottlieb AB, Segal T, Politi Y, Maron L, Sulkes J, et al. Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation. J Am Acad Dermatol. 2003;49:451-7.
16. Hodak E, Gottlieb AB, Segal T, Maron L, Lotem M, Feinmesser M, et al. An open trial of climatotherapy at the Dead Sea for patch-stage mycosis fungoides. J Am Acad Dermatol. 2004;51:33-8.
17. Kudish AI, Abels D, Harari M. Ultraviolet radiation properties as applied to photoclimatherapy at the Dead Sea. Int J Dermatol. 2003;42:359-65.
18. Kushelevsky AP, Harari M, Hristakieva E, Shani J. Climatotherapy of psoriasis and hypertension in elderly patients at the Dead-Sea. Pharmacol Res. 1996;34:87-91.
19. Kushelevsky AP, Harari M, Kudish AI, Hristakieva E, Ingber A, Shani J. Safety of solar phototherapy at the Dead Sea. J Am Acad Dermatol. 1998;38:447-52.
20. Matz H, Orion E, Wolf R. Balneotherapy in dermatology. Dermatol Ther. 2003;16:132-40.
21. Montgomery BJ. Bathing for psoriasis in the Dead Sea. JAMA. 1979;241:227-31.
22. Paltiel O, Adler B, Herschko K, Tsukrov B, David M. Are patients with psoriasis susceptible to the classic risk factors for actinic keratoses? Arch Dermatol. 2004;140:805-10.
23. Sapeika N. Treatment of psoriasis at the Dead Sea. S Afr Med J. 1976;50:2021.
24. Schamberg IL. Treatment of psoriasis at the Dead Sea. Int J Dermatol. 1978;17:524-5.
25. Schiffner R, Schiffher-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W. Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications. Br J Dermatol. 2001;144:1154-60.
26. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol. 2003;148:1153-60.
27. Shani J, Harari M, Hristakieva E, Seidl V, Bar-Giyora J. Dead-Sea climatotherapy versus other modalities of treatment for psoriasis: comparative cost-effectiveness. Int J Dermatol. 1999;38:252-62.
28. Weinrauch L. The cost of psoriasis treatment at the Dead Sea. Int J Dermatol. 1996;35:150-1.
29. Wolf R, Orion E, Matz H. Climatotherapy: there is life in the Dead Sea. Isr Med Assoc J. 2003;5:124-5.
30. Schallreuter KU, Moore J, Behrens-Williams S, Panske A, Harari M. Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol. 2002;41:482-7.
31. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 1978;157:238-44.
32. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859-66.
33. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-33.
34. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-27.